Claremont, CA (PRWEB) April 04, 2012
Pathogenic bacteria use the body’s own cell surfaces to gain a foothold to establish an infection in human tissue. Synedgen, in collaboration with DARPA (Defense Advanced Research Projects Agency), is circumventing this harmful grip by blocking the bacteria’s ability to stick to the cells and by clumping the bacteria together for easy rinsing from a wound. This prevention of bacterial adhesion and biofilm formation is critical in the prevention of infection.
Synedgen’s newly developed wound irrigation rinse, Catasyn, safely prevents and treats infections in acute wounds and simultaneously stimulates the wound healing process. DARPA has awarded Synedgen a 12-month, $500k development grant to accelerate the submission of a pre-Investigational New Drug (IND) application to the FDA. This research addresses an urgent need for the prevention and management of wound infections and the healthy regeneration of wound tissue.
Wound care and chronic infection from complications related to Improvised Explosive Devices (IED) injury in soldiers is a major medical concern for DARPA and the US military. Bacterial infections are common in IED and other traumatic injuries, yet increasing rates of antibiotic resistance make the use of prophylactic antibiotics difficult, limiting treatment and recovery. Once the infection takes hold, multi drug resistant bacteria, such as methicillin resistant Staphylococcus aureus and Acinetobacter baumaunnii, are even more difficult to treat because they become protected in the biofilms they form and they have expanding resistance to traditional antibiotics.
This award leverages previous Synedgen wound research, which demonstrated remarkable antimicrobial activity against drug resistant organisms as well as significant ability to promote the healing process. During this effort, Synedgen will optimize the ability of the rinse to treat and prevent infections as well as stimulate wound healing in animal models. Additionally, Synedgen will optimize the treatment regimen for human use and complete other product validation requirements necessary to begin FDA regulatory approval for use in human subjects.
“While commonly used antiseptics and wound irrigation products are harmful to human tissue, our wound rinse encourages wound closure and is effective against both resistant Gram-positive and Gram-negative bacteria and their biofilms,” remarked Synedgen CEO Dr. William Wiesmann. “Unlike traditional antibiotic based treatments, which are based on killing bacteria and can cause bacterial resistance, our wound rinse prevents binding and invasion of bacteria. Equally important, our rinse has residual activity to provide longer-term protection.”
“Catasyn has been demonstrated to remove established biofilms from infected wounds, which is an unmet need both in military and civilian settings. We are eager to accelerate the development of Synedgen’s wound care products that safely provide a revolutionary breakthrough for preventing and treating drug resistant infections,” stated Synedgen President Shenda Baker.
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. This platform technology provides the foundation for preventing bacterial growth and disruption of biofilms in human and environmental applications. Product development is targeted to specifically address unmet needs for therapies that treat and prevent infections, primarily from bacteria that have developed resistance to traditional antibiotics.
Synedgen’s Corporate Headquarters and Research Laboratories are in Claremont CA; Synedgen’s Manufacturing Facility is in Honolulu HI. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.